Carprieve 100 mg Tablets for Dogs

i. Special precautions for use in animals
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, such dogs may require a reduced dosage
and careful clinical management.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of
inflammatory conditions associated with bacterial infection, appropriate
concurrent antimicrobial therapy should be instigated.
Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive
dog, as there is a potential risk of increased renal toxicity.
Refer to section 4.8
ii. Special precautions to be taken by the person administering the veterinary
medicinal product to animals
In the event of accidental ingestion of the tablets, seek medical advice and
show the doctor the package leaflet.
Wash hands after handling the product.
4.6 Adverse reactions (frequency and seriousness)
Typical undesirable effects associated with NSAIDs such as vomiting, soft
faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been
reported. These adverse reactions occur generally within the first treatment
week and are in most cases transient and disappear following termination of
the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the
advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic
adverse events.
4.7 Use during pregnancy, lactation or lay
Studies in laboratory species (rat and rabbit) have shown evidence of
foetotoxic effects of carprofen at doses close to the therapeutic dose. The
safety of the veterinary medicinal product has not been established during
pregnancy and lactation. Do not use in pregnant or lactating bitches.

Revised: June 2014
AN: 00391/2013
4.8 Interaction with other medicinal products and other forms of interaction
Do not administer other NSAIDs and glucocorticoids concurrently or within 24
hours of each other. Some NSAIDs may be highly bound to plasma proteins
and compete with other highly bound drugs, which can lead to toxic effects.
Concurrent administration of potential nephrotoxic drugs should be avoided.
4.9 Amounts to be administered and administration route
For oral administration.
4 mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single
dose or in two equally divided doses. The daily dose may be reduced, subject
to clinical response.
Duration of treatment will be dependent upon the response seen. Long-term
treatment should be under regular veterinary supervision.
Do not exceed the stated dose.
To extend analgesic and anti-inflammatory cover post-operatively parenteral
pre-operative treatment with an injectable Carprofen product may be followed
with Carprofen Tablets at 4 mg/kg/day for up to 5 days.
Return any halved tablets to the original pack and use at the next
administration.
Any halved tablets remaining after the last administration of the product must be
discarded
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Do not exceed the stated dose. There is no specific antidote for carprofen
overdosage but general supportive therapy, as applied to clinical overdosage
with NSAIDs should be applied.
4.11 Withdrawal Period(s)
Not applicable
5.